MENU
+Compare
ENLV
Stock ticker: NASDAQ
AS OF
Sep 26, 03:55 PM (EDT)
Price
$1.02
Change
-$0.01 (-0.97%)
Capitalization
24.57M

ENLV Enlivex Therapeutics Ltd Forecast, Technical & Fundamental Analysis

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company... Show more

ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ENLV with price predictions
Sep 25, 2025

ENLV's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ENLV turned positive on September 12, 2025. Looking at past instances where ENLV's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ENLV advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 48 cases where ENLV's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on September 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ENLV as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 10-day moving average for ENLV crossed bearishly below the 50-day moving average on August 27, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENLV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.290) is normal, around the industry mean (19.661). P/E Ratio (0.000) is within average values for comparable stocks, (53.961). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.097). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (344.769).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ENLV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ENLV is expected to report earnings to rise 27.77% to -14 cents per share on December 01

Enlivex Therapeutics Ltd ENLV Stock Earnings Reports
Q3'25
Est.
$-0.14
Q2'25
Beat
by $0.04
Q1'25
Beat
by $0.01
Q4'24
Missed
by $0.07
Q3'24
Beat
by $0.03
The last earnings report on August 18 showed earnings per share of -11 cents, beating the estimate of -15 cents. With 67.84K shares outstanding, the current market capitalization sits at 24.57M.
A.I. Advisor
published General Information

General Information

a developer of autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
14 Einstein Street
Phone
+972 26208072
Employees
77
Web
https://www.enlivex.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RUSHB58.23-0.19
-0.33%
Rush Enterprises
MFC30.67-0.30
-0.97%
Manulife Financial Corp
LOMA7.73-0.23
-2.89%
Loma Negra Compania Industrial Argentina Sociedad Anonima
GFAI1.13-0.04
-3.42%
Guardforce AI Co Limited
BTCS4.52-0.33
-6.80%
BTCS

ENLV and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ENLV has been loosely correlated with APVO. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ENLV jumps, then APVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENLV
1D Price
Change %
ENLV100%
-1.44%
APVO - ENLV
36%
Loosely correlated
-10.11%
FENC - ENLV
26%
Poorly correlated
+3.57%
OCUL - ENLV
24%
Poorly correlated
-2.55%
BBIO - ENLV
24%
Poorly correlated
-3.26%
KZIA - ENLV
24%
Poorly correlated
-6.98%
More